Figure 3.
Cost-effectiveness of routine PCV13 childhood vaccination
The graphs show ICERs of PCV13 vaccination versus no vaccination, by country, compared with cost-effectiveness thresholds based on average values reported by Woods and colleagues28 (A) and thresholds based on GDP (at PPP) per capita (B). The x-axis represents the cost-effectiveness estimate obtained from our model. Countries above the line (y=x) are cost-effective. Graphs are presented using a log-log scale. Credible intervals were omitted for clarity. DALY=disability-adjusted life-year. GDP=gross domestic product. ICER=incremental cost-effectiveness ratio. I$=international dollars. PCV13=13-valent pneumococcal conjugate vaccine. PPP=purchasing power parity.